SDCTA Opposes California Cancer Research Act
Revenue generated from this proposed excise tax may not be enough to meet the financial obligations of the new programs that would be established by this measure. It is estimated that $75 million of the revenue from the Cancer Research Act would go toward backfill funding for previously approved programs in its first full fiscal year and would be expected to increase every year thereafter. Further, this measure would create a new level of state bureaucracy with little oversight over how the funds are allocated and lack of control by any other California government entity to oversee the expenditure of the funds.